Tuberculosis RSS feed: Articles in Press. Tuberculosis is a speciality journal focusing on basic experimental research on tuberculosis, notably on bacteriological, immunological and pathogenesis aspects of the disease. The journal publishes original research and reviews on the host response and immunology of tuberculosis and the molecular biology, genetics and physiology of the organism. Areas covered include: immunology immunogenetics pathogenetics microbiology microbial physiology pathogenesis pathology molecular epidemiology diagnostics vaccine development drug resistance The resurgence of interest in tuberculosis has accelerated the pace of relevant research and Tuberculosis has grown with it, as the only journal dedicated to experimental biomedical research in tuberculosis. To view the benefits of Online Submission please click here. http://www.tuberculosisjournal.com//inpress?rss=yesElsevier Inc.en © 2010 Elsevier Ltd. All rights reserved. Tuberculosis1472-97922010-07-26 © 2010 Elsevier Ltd. All rights reserved. healthpermissions@elsevier.comhttp://www.tuberculosisjournal.com/article/PIIS1472979210000685/abstract?rss=yesSummary: There have been multiple explanations put forward to try to explain the variable efficacy of the BCG vaccine. Here I propose the new hypothesis that the primary flaw of BCG is its inability to effectively establish a population of central memory T cells. Instead, the vaccine establishes immunity represented by effector memory T cells; these distribute in the lungs and may protect humans for 10–15 years but are gradually lost. With no central memory response to compensate, the individual loses any further resistance to tuberculosis. This may have serious implications for vaccine design, given the emphasis on developing recombinant forms of BCG.The Achilles heel of BCG - Corrected ProofIan M. Orme10.1016/j.tube.2010.06.002Tuberculosis (2010)2010-07-26Tuberculosis2010-07-26http://www.tuberculosisjournal.com/article/PIIS1472979210000673/abstract?rss=yesSummary: The increase of incidence of tuberculosis (TB) with resistant strains and HIV co-infection has reinforced the necessity of developing new drugs for its treatment. The reaction of naphthoquinones with aromatic or aliphatic aldehydes in the presence of ammonium acetate led to the synthesis of the three β-lapachone derivatives (naphthoimidazoles) that were tested in this study. Phenazines were prepared by the reaction of the respective naphtoquinone with o-phenylenediamine in acetic acid under reflux. The antimicrobial activity of the derivatives was evaluated in vitro against Mycobacterium tuberculosis H37Rv (ATCC 27294) and the rifampicin-resistant strain (ATCC 35338) containing a His-526-Tir mutation in the rpoB gene. Using the Resazurin Microtiter Assay (REMA) method, bioactive molecules were observed in the susceptible and resistant strains with MICs ranging from 2.2 μM to 17 μM. The naphthoimidazoles with p-toluyl and indolyl group attached to the imidazole ring were more active against the H37Rv strain (MIC 9.12 μM and 4.2 μM, respectively) than the rifampicin-resistant strain (MIC 8.3 μM and 17 μM, respectively). The phenazine with the allyl-pyran group was most active among the two strains and had an MIC of 2.2 μM. These results show the potential of these molecules as prototypes for future drugs used in treating TB.Activity of β-lapachone derivatives against rifampicin-susceptible and -resistant strains of Mycobacterium tuberculosis - Corrected ProofTatiane S. Coelho, Raphael S.F. Silva, Antonio V. Pinto, Maria C.F.R. Pinto, Carlos J. Scaini, Kelly C.G. Moura, Pedro Almeida da Silva10.1016/j.tube.2010.06.001Tuberculosis (2010)2010-07-22Tuberculosis2010-07-22DRUG DISCOVERY AND RESISTANCEhttp://www.tuberculosisjournal.com/article/PIIS1472979204000721/abstract?rss=yesSummary: In this brief review I will discuss some of the more interesting [and in some cases, confusing] aspects that have arisen from the current NIH-funded TB vaccine screening program at Colorado State University, how they affect our understanding of the vaccination process, and how this may influence the rational vaccine design in the near future.Mouse and guinea pig models for testing new tuberculosis vaccines - Corrected ProofIan M. Orme10.1016/j.tube.2004.09.004Tuberculosis (2005)2005-01-17Tuberculosis2005-01-17